Chronic vagal nerve stimulation has no effect on tachycardia-induced heart failure progression or excitation-contraction coupling.
calcium
heart failure
parasympathetic
tachycardia-induced cardiomyopathy
vagal nerve stimulation
Journal
Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
02
09
2019
revised:
25
11
2019
accepted:
28
11
2019
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
2
1
2021
Statut:
ppublish
Résumé
Autonomic dysregulation plays a key role in the development and progression of heart failure (HF). Vagal nerve stimulation (VNS) may be a promising therapeutic approach. However, the outcomes from clinical trials evaluating VNS in HF have been mixed, and the mechanisms underlying this treatment remain poorly understood. Intermittent high-frequency VNS (pulse width 300 µs, 30 Hz stimulation, 30 s on, and 300 s off) was used in healthy sheep and sheep in which established HF had been induced by 4 weeks rapid ventricular pacing to assess (a) the effects of VNS on intrinsic cardiac vagal tone, (b) whether VNS delays the progression of established HF, and (c) whether high-frequency VNS affects the regulation of cardiomyocyte calcium handling in health and disease. VNS had no effect on resting heart rate or intrinsic vagal tone in the healthy heart. Although fewer VNS-treated animals showed subjective signs of heart failure at 6 weeks, overall VNS did not slow the progression of clinical or echocardiographic signs of HF. Chronic VNS did not affect left ventricular cardiomyocyte calcium handling in healthy sheep. Rapid ventricular pacing decreased the L-type calcium current and calcium transient amplitude, but chronic VNS did not rescue dysfunctional calcium handling. Overall, high-frequency VNS did not prevent progression of established HF or influence cellular excitation-contraction coupling. However, a different model of HF or selection of different stimulation parameters may have yielded different results. These results highlight the need for greater insight into VNS dosing and parameter selection and a deeper understanding of its physiological effects.
Identifiants
pubmed: 31961064
doi: 10.14814/phy2.14321
pmc: PMC6971309
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14321Subventions
Organisme : Medical Research Council
ID : MR/K5002823/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH200004/12801
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/52/28678
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/12/34/29465
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/12/57/29717
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/56/30645
Pays : United Kingdom
Organisme : British Heart Foundation
ID : IG/15/2/31514
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/10/71/28567
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
Références
Ann Intern Med. 2009 Jun 2;150(11):784-94
pubmed: 19487713
Front Physiol. 2018 Oct 04;9:1380
pubmed: 30337881
Circ Heart Fail. 2009 Nov;2(6):692-9
pubmed: 19919995
Am J Physiol Heart Circ Physiol. 2015 Nov 15;309(10):H1740-52
pubmed: 26371171
J Am Heart Assoc. 2018 Dec 4;7(23):e009972
pubmed: 30520673
N Engl J Med. 1984 Sep 27;311(13):819-23
pubmed: 6382011
Circulation. 2004 Jan 6;109(1):120-4
pubmed: 14662714
Eur Heart J. 2015 Feb 14;36(7):425-33
pubmed: 25176942
Exp Physiol. 2001 Jan;86(1):1-12
pubmed: 11429613
Sci Rep. 2019 May 1;9(1):6801
pubmed: 31043634
J Physiol. 2017 Nov 15;595(22):6887-6903
pubmed: 28862330
N Engl J Med. 1971 Oct 14;285(16):877-83
pubmed: 4398792
Eur J Heart Fail. 2008 Sep;10(9):884-91
pubmed: 18760668
Eur J Heart Fail. 2013 Dec;15(12):1319-26
pubmed: 23883651
Am Heart J. 2006 Oct;152(4):713.e9-13
pubmed: 16996845
J Physiol. 2011 Mar 15;589(Pt 6):1367-82
pubmed: 21242250
Pflugers Arch. 1993 Apr;423(1-2):158-60
pubmed: 8488088
Cardiovasc Res. 1998 Jul;39(1):60-76
pubmed: 9764190
Eur Heart J. 2011 Apr;32(7):847-55
pubmed: 21030409
Circ Res. 2014 Dec 5;115(12):986-96
pubmed: 25332206
Dev Biol. 1981 Jun;84(2):286-90
pubmed: 20737866
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Circ Heart Fail. 2010 Jan;3(1):35-43
pubmed: 19850696
J Physiol. 2017 Oct 1;595(19):6263-6279
pubmed: 28752958
Heart Fail Rev. 2011 Mar;16(2):129-35
pubmed: 20820912
J Physiol. 2013 Sep 15;591(18):4515-33
pubmed: 23818689
Circulation. 1998 Oct 13;98(15):1510-6
pubmed: 9769304
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1544-1552
pubmed: 26707382
J Am Coll Cardiol. 2016 Jul 12;68(2):149-58
pubmed: 27058909
Circulation. 1999 Jun 8;99(22):2958-63
pubmed: 10359742
Circulation. 2001 Mar 20;103(11):1577-84
pubmed: 11257088
J Mol Cell Cardiol. 2004 Dec;37(6):1171-81
pubmed: 15572047
J Mol Cell Cardiol. 2015 Feb;79:169-79
pubmed: 25463272
J Card Fail. 2014 Nov;20(11):808-16
pubmed: 25187002
Circ Res. 2003 Apr 4;92(6):651-8
pubmed: 12600875